AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,294,739 | -8.6% | 2,244,633 | -5.6% | 0.00% | 0.0% |
| Q2 2023 | $29,879,009 | +7.8% | 2,378,902 | -4.8% | 0.00% | 0.0% |
| Q1 2023 | $27,725,732 | -3.5% | 2,500,066 | +6.3% | 0.00% | 0.0% |
| Q4 2022 | $28,721,547 | +28.3% | 2,352,297 | +9.7% | 0.00% | 0.0% |
| Q3 2022 | $22,388,000 | +2.3% | 2,144,445 | +5.3% | 0.00% | +50.0% |
| Q2 2022 | $21,876,000 | -6.0% | 2,036,853 | -17.1% | 0.00% | 0.0% |
| Q1 2022 | $23,266,000 | +0.1% | 2,456,806 | +22.1% | 0.00% | 0.0% |
| Q4 2021 | $23,251,000 | +34.3% | 2,012,920 | +11.0% | 0.00% | 0.0% |
| Q3 2021 | $17,315,000 | +2.0% | 1,813,090 | +2.9% | 0.00% | 0.0% |
| Q2 2021 | $16,981,000 | -14.5% | 1,761,606 | -12.4% | 0.00% | 0.0% |
| Q1 2021 | $19,872,000 | -14.0% | 2,011,355 | +101.1% | 0.00% | -33.3% |
| Q4 2020 | $23,097,000 | +92.5% | 1,000,300 | +17.7% | 0.00% | +50.0% |
| Q3 2020 | $11,999,000 | +14.0% | 849,889 | +21.7% | 0.00% | 0.0% |
| Q2 2020 | $10,527,000 | +44.3% | 698,096 | -11.5% | 0.00% | +100.0% |
| Q1 2020 | $7,293,000 | +23.0% | 789,243 | +29.7% | 0.00% | 0.0% |
| Q4 2019 | $5,930,000 | -65.1% | 608,693 | -71.2% | 0.00% | -50.0% |
| Q3 2019 | $16,975,000 | -34.2% | 2,116,707 | +2.4% | 0.00% | -50.0% |
| Q2 2019 | $25,788,000 | -14.5% | 2,066,427 | -6.8% | 0.00% | -20.0% |
| Q1 2019 | $30,153,000 | +90.4% | 2,217,160 | +34.1% | 0.01% | +66.7% |
| Q4 2018 | $15,838,000 | -36.0% | 1,653,206 | -19.2% | 0.00% | -25.0% |
| Q3 2018 | $24,750,000 | +132.9% | 2,047,159 | +200.8% | 0.00% | +100.0% |
| Q2 2018 | $10,629,000 | -0.3% | 680,464 | -4.0% | 0.00% | +100.0% |
| Q1 2018 | $10,661,000 | +3.5% | 708,880 | -1.0% | 0.00% | -50.0% |
| Q4 2017 | $10,302,000 | +18.1% | 715,917 | +23.8% | 0.00% | +100.0% |
| Q3 2017 | $8,722,000 | +1293.3% | 578,413 | +830.8% | 0.00% | – |
| Q2 2017 | $626,000 | +12.4% | 62,143 | -20.5% | 0.00% | – |
| Q1 2017 | $557,000 | -41.7% | 78,216 | -59.3% | 0.00% | – |
| Q4 2016 | $955,000 | +85.8% | 192,203 | +176.7% | 0.00% | – |
| Q3 2016 | $514,000 | +49.9% | 69,465 | +10.7% | 0.00% | – |
| Q2 2016 | $343,000 | -80.2% | 62,750 | -69.5% | 0.00% | – |
| Q1 2016 | $1,736,000 | +146.9% | 205,462 | +183.8% | 0.00% | – |
| Q4 2015 | $703,000 | -55.5% | 72,392 | -35.9% | 0.00% | – |
| Q3 2015 | $1,580,000 | +76.9% | 112,881 | +79.0% | 0.00% | – |
| Q2 2015 | $893,000 | +135.0% | 63,074 | +80.2% | 0.00% | – |
| Q1 2015 | $380,000 | +146.8% | 35,000 | +89.3% | 0.00% | – |
| Q4 2014 | $154,000 | -34.7% | 18,489 | -53.4% | 0.00% | – |
| Q3 2014 | $236,000 | -29.1% | 39,700 | -60.1% | 0.00% | – |
| Q2 2014 | $333,000 | +8225.0% | 99,484 | +4701.4% | 0.00% | – |
| Q1 2014 | $4,000 | -90.2% | 2,072 | -88.2% | 0.00% | – |
| Q4 2013 | $41,000 | +925.0% | 17,499 | +899.9% | 0.00% | – |
| Q3 2013 | $4,000 | -55.6% | 1,750 | -54.0% | 0.00% | – |
| Q2 2013 | $9,000 | – | 3,804 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |